Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,807 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Disorder Clear all
Completed No phase listed Observational

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

NCT05233592
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
CGM
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

NCT00988858
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
LY2603618, Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Tucson, Arizona • Denver, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Carbon Monoxide to Prevent Lung Inflammation

NCT00094406
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Bronchoscopy, Bronchoalveolar lavage, Endotoxin, Carbon Monoxide
Procedure · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 40 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

NCT00101348
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Colon Cancer, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
erlotinib hydrochloride, cetuximab, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

SRS Study in Patients With Non-Small Cell Lung Cancer

NCT00489008
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

NCT00649025
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
21
States / cities
Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT04513925
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Atezolizumab, Tiragolumab, Durvalumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
Palo Alto, California • Greeley, Colorado • Fort Myers, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Not applicable Interventional

Long COVID-19 Rehabilitation & Recovery Research Program

NCT05398692
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, COVID-19
Interventions
On Site Exercise Rehabilitation
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
ofatumumab, ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings

NCT04726371
View directory record Official record
Conditions
Intellectual Disability, Developmental Disability, Axis I Diagnosis, Mental Illness, Covid19, Coronavirus
Interventions
Generic Best Practices, Tailored Best Practices
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 11, 2026, 2:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

NCT05908734
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetrelimab, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Alamitos, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

NCT04631016
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
Interventions
Tozorakimab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Sheffield, Alabama • Newport Beach, California • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 11, 2026, 2:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Long COVID-19 Intervention Using Digital Health & Technology

NCT05616806
View directory record Official record
Conditions
Long COVID, Distress Tolerance
Interventions
iENDURE
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform

NCT03737149
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
mymobility with Apple Watch
Other
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
6,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
26
States / cities
Fremont, California • Irvine, California • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Active, not recruiting No phase listed Observational

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

NCT05415358
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Blood and tissue samples
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

NCT01572948
View directory record Official record
Conditions
COPD
Interventions
roflumilast, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

NCT00740636
View directory record Official record
Conditions
Lung Cancer
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional Results available

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

NCT04668209
View directory record Official record
Conditions
Coronavirus
Interventions
Silmitasertib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 11, 2026, 2:56 AM EDT
Suspended Phase 1 Interventional

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

NCT01604863
View directory record Official record
Conditions
Cancer
Interventions
HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Phase 3 Interventional Results available

Pulmonary Rehabilitation Before Lung Cancer Resection

NCT02887521
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
education, rehabilitation, pedometer, surgery
Other · Procedure · Device
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 11, 2026, 2:56 AM EDT
Not listed Phase 4 Interventional

Assessing Decision Maker Tools for Asthma: the Asthma APGAR

NCT01446315
View directory record Official record
Conditions
Asthma
Interventions
Use of Asthma APGAR system and tools, Asthma APGAR tools
Behavioral
Lead sponsor
Olmsted Medical Center
Other
Eligibility
5 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

NCT04871815
View directory record Official record
Conditions
Long COVID
Interventions
sodium pyruvate nasal spray
Drug
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

NCT04762771
View directory record Official record
Conditions
Covid19
Interventions
Colchicine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 11, 2026, 2:56 AM EDT